- Home
- VTYX vs LFVN Comparison
VTYX vs LFVN Comparison
Compare VTYX & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- LFVN
- Stock Information
- Founded
- VTYX 2018
- LFVN N/A
- Country
- VTYX United States
- LFVN United States
- Employees
- VTYX N/A
- LFVN N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- LFVN Biotechnology: Pharmaceutical Preparations
- Sector
- VTYX Health Care
- LFVN Health Care
- Exchange
- VTYX Nasdaq
- LFVN Nasdaq
- Market Cap
- VTYX 154.9M
- LFVN 165.9M
- IPO Year
- VTYX 2021
- LFVN N/A
- Fundamental
- Price
- VTYX $1.70
- LFVN $13.05
- Analyst Decision
- VTYX Buy
- LFVN Strong Buy
- Analyst Count
- VTYX 4
- LFVN 2
- Target Price
- VTYX $11.33
- LFVN $30.50
- AVG Volume (30 Days)
- VTYX 1.5M
- LFVN 215.9K
- Earning Date
- VTYX 05-08-2025
- LFVN 05-06-2025
- Dividend Yield
- VTYX N/A
- LFVN 1.38%
- EPS Growth
- VTYX N/A
- LFVN 152.87
- EPS
- VTYX N/A
- LFVN 0.70
- Revenue
- VTYX N/A
- LFVN $222,347,000.00
- Revenue This Year
- VTYX N/A
- LFVN $17.36
- Revenue Next Year
- VTYX N/A
- LFVN $9.60
- P/E Ratio
- VTYX N/A
- LFVN $18.62
- Revenue Growth
- VTYX N/A
- LFVN 8.22
- 52 Week Low
- VTYX $0.78
- LFVN $5.22
- 52 Week High
- VTYX $5.66
- LFVN $27.38
- Technical
- Relative Strength Index (RSI)
- VTYX 61.97
- LFVN 51.11
- Support Level
- VTYX $1.68
- LFVN $12.58
- Resistance Level
- VTYX $1.85
- LFVN $13.53
- Average True Range (ATR)
- VTYX 0.15
- LFVN 0.72
- MACD
- VTYX 0.04
- LFVN 0.13
- Stochastic Oscillator
- VTYX 67.05
- LFVN 74.22
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.